Empyrean Neuroscience

Empyrean Neuroscience is pioneering a novel approach to drug discovery by genetically engineering fungi and plants to create new small molecule therapeutics for severe neurological and neuropsychiatric disorders. The company has built what it claims is the first and only platform capable of this specific application of genetic engineering, combining capabilities in bioinformatics, transformation, and regeneration. Founded in 2021 and based in London with an additional office in Cambridge, UK, and an operational presence in New York, Empyrean is a private, pre-clinical stage company focused on translating its platform into a pipeline of first-in-class human therapeutics. Its strategy targets a significant gap in treatment options for debilitating conditions where current therapies are often inadequate.

Proprietary platform for genetically engineering fungi and plants to up-regulate, down-regulate, or modify genes to create novel neuroactive small molecule therapeutics. Integrates bioinformatics, transformation/regeneration methods, and scalable GMP manufacturing.

Competes with biopharma companies developing psychedelic/entactogen derivatives, novel antidepressants, and non-opioid pain therapies. Its unique differentiator is the direct genetic engineering of fungi/plants as bioreactors, a more directed approach compared to traditional natural product extraction or synthetic chemistry. Faces competition from other platform companies in synthetic biology and computational drug discovery.